Concepedia
Statistics
Publications
8
Citations
455
H-Index
Active since
2008
Affiliations
Charité - Universitätsmedizin Berlin(Current)
Zero to Three
Novartis (United States)
Medizinische Hochschule Hannover
Novartis (Switzerland)
Britta Lamottke is an author at Charité - Universitätsmedizin Berlin specializing in medicine, oncology, and cancer pharmacology.
Publications per year
2008–2023
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma
Ulrike Heider, Jessica Rademacher, Britta Lamottke et al. · European Journal Of Haematology · 2009 · 172 citations
Medicine, Oncology, Pharmacology +15
A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency
Katharina Wimmer, Andreas Beilken, R. Nustede et al. · Familial Cancer · 2016 · 76 citations · Full text
Life Sciences, Genetics, Molecular Genetics +16
Serum concentrations of DKK‐1 decrease in patients with multiple myeloma responding to anti‐myeloma treatment
Ulrike Heider, Martin Kaiser, Maren Mieth et al. · European Journal Of Haematology · 2008 · 71 citations · Full text
Medicine, Hematology, Oncology +13
Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
Martin Kaiser, Britta Lamottke, Maren Mieth et al. · European Journal Of Haematology · 2009 · 44 citations
Medicine, Oncology, Pharmacology +14
Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
Agnes Bonifacius, Britta Lamottke, Sabine Tischer‐Zimmermann et al. · Journal of Clinical Investigation · 2023 · 42 citations · Full text
Life Sciences, Immunology, Infectious Diseases +17
1–5 of 8